Recent advances in renal interstitial fibrosis and tubular atrophy after kidney transplantation

Fibrogenesis and Tissue Repair

Volumn 7, Issue 1, 2014, Pages

  Li, Xiaojun ^a   Zhuang, Shougang ^a,b  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b BROWN UNIVERSITY   (United States)

Author keywords

Interstitial fibrosis; Renal allograft loss; Renal transplantation; Tubular atrophy

Indexed keywords

25 HYDROXYVITAMIN D; CALCINEURIN INHIBITOR; CHEMOKINE RECEPTOR CCR7; COMPLEMENT COMPONENT C4D; CONNECTIVE TISSUE GROWTH FACTOR; CYCLOSPORIN; DNA; EVEROLIMUS; HLA ANTIBODY; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOSUPPRESSIVE AGENT; MATRIX METALLOPROTEINASE; MESSENGER RNA; MICRORNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NORCANTHARIDIN; OSTEOGENIC PROTEIN 1; RAPAMYCIN; RECOMBINANT ERYTHROPOIETIN; RETINOL BINDING PROTEIN; SECONDARY LYMPHOID TISSUE CHEMOKINE; SYNDECAN 1; TACROLIMUS; THIOCTIC ACID; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; VITAMIN D BINDING PROTEIN;

ANTIBODY MEDIATED REJECTION; ATROPHY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG MEGADOSE; EPITHELIAL MESENCHYMAL TRANSITION; GLOMERULOPATHY; GRAFT RECIPIENT; HUMAN; HYALINE DEGENERATION; KIDNEY ALLOGRAFT REJECTION; KIDNEY FIBROSIS; KIDNEY TRANSPLANTATION; KIDNEY TUBULE DISORDER; MACROPHAGE; MESENCHYMAL STEM CELL TRANSPLANTATION; MICROANGIOPATHY; MICROCHIMERISM; MONOCYTE; NEPHRITIS; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; SIGNAL TRANSDUCTION; TUBULAR ATROPHY; UNSPECIFIED SIDE EFFECT;

EID: 84908101181     PISSN: None     EISSN: 17551536     Source Type: Journal    
DOI: 10.1186/1755-1536-7-15     Document Type: Review

References (142)

1. Solez K, Colvin RB, Racusen LC, Sis B, Halloran PF, Birk PE, Campbell PM, Cascalho M, Collins AB, Demetris AJ, Drachenberg CB, Gibson IW, Grimm PC, Haas M, Lerut E, Liapis H, Mannon RB, Marcus PB, Mengel M, Mihatsch MJ, Nankivell BJ, Nickeleit V, Papadimitriou JC, Platt JL, Randhawa P, Roberts I, Salinas-Madriga L, Salomon DR, Seron D, Sheaff M, et al. Banff-05 meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (CAN). Am J Transplant 2007, 7:518-526. 10.1111/j.1600-6143.2006.01688.x, 17352710.
2. Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005, 16:3015-3026. 10.1681/ASN.2005050463, 16120819.
3. Nankivell BJ, Fenton-Lee CA, Kuypers DR, Cheung E, Allen RD, O'Connell PJ, Chapman JR. Effect of histological damage on long-term kidney transplant outcome. Transplantation 2001, 71:515-523. 10.1097/00007890-200102270-00006, 11258430.
4. Serón D, Moreso F, Ramón JM, Hueso M, Condom E, Fulladosa X, Bover J, Gil-Vernet S, Castelao AM, Alsina J, Grinyó JM. Protocol renal allograft biopsies andthe design of clinical trials aimed to prevent or treat chronic allograft nephropathy. Transplantation 2000, 69:1849-1855. 10.1097/00007890-200005150-00019, 10830221.
5. Butzal M, Loges S, Schweizer M, Fischer U, Gehling UM, Hossfeld DK, Fiedler W. Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cellsin vitro. Exp Cell Res 2004, 300(1):65-71. 10.1016/j.yexcr.2004.07.002, 15383315.
6. Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a U.S. Multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 kidney transplant study group. Transplantation 1998, 66:1736-1740. 10.1097/00007890-199812270-00029, 9884269.
7. Olyaei AJ, de Mattos AM, Bennett WM. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr Opin Crit Care 2001, 7(6):384-389. 10.1097/00075198-200112000-00003, 11805539.
8. Khanna A, Plummer M, Bromberek C, Bresnahan B, Hariharan S. Expression of TGF-b and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity. Kidney Int 2002, 62:2257-2263. 10.1046/j.1523-1755.2002.00668.x, 12427154.
9. Wolf G. Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-b pathway. Kidney Int 2006, 70:1914-1919.
10. Feldman G, Kiely B, Martin N, Ryan G, McMorrow T, Ryan MP. Role for TGF-b in cyclosporine-induced modulation of renal epithelial barrier function. J Am Soc Nephrol 2007, 18:1662-1671. 10.1681/ASN.2006050527, 17460148.
11. Wang S, Wilkes MC, Leof EB, Hirschberg R. Noncanonical TGF-beta pathways, mTORC1 and Ab1, in renal interstitial fibrogenesis. Am J Physiol Renal Physiol 2010, 298:F142-F149. 10.1152/ajprenal.00320.2009, 2806113, 19846571.
12. Alpay N, Ozkok A, Caliskan Y, Akagun T, Cinar SA, Deniz G, Sariyar M, Yildiz A. Influenceof conversion fromcalcineurin inhibitors to everolimus on fibrosis, inflammation, tubular damage and vascular function in renal transplantpatients. Clin Exp Nephrol 2014, Feb 11. [Epub ahead of print].
13. Kurdián M, Herrero-Fresneda I, Lloberas N, Gimenez-Bonafe P, Coria V, Grande MT, Boggia J, Malacrida L, Torras J, Arévalo MA, González-Martínez F, López-Novoa JM, Grinyó J, Noboa O. Delayed mTOR inhibition with low dose of everolimus reduces TGFb expression, attenuates proteinuria and renal damage in the renal mass reduction model. PLoS One 2012, 7(3):e32516. 10.1371/journal.pone.0032516, 3299670, 22427849.
14. Pontrelli P, Rossini M, Infante B, Stallone G, Schena A, Loverre A, Ursi M, Verrienti R, Maiorano A, Zaza G, Ranieri E, Gesualdo L, Ditonno P, Bettocchi C, Schena FP, Grandaliano G. Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy. Transplantation 2008, 85:125-134. 10.1097/01.tp.0000296831.91303.9a, 18192922.
15. Gonzalez F, Espinoza M, Reynolds E, Herrera P, Espinoza O, Rocca X, Lorca E, Hidalgo J, Roessler E. Effectiveness and cost of replacing a calcineurin inhibitor with sirolimus to slow the course of chronic kidney disease in renal allografts. Transplant Proc 2010, 42:284-287. 10.1016/j.transproceed.2009.12.049, 20172332.
16. Servais A, Meas-Yedid V, Toupance O, Lebranchu Y, Thierry A, Moulin B, Etienne I, Presne C, de LB H, Le Pogamp P, Le Meur Y, Glotz D, Hayem C, Olivo Marin JC, Thervet E. Interstitial fibrosis quantification in renal transplant recipients randomized to continue cyclosporine or convert to sirolimus. Am J Transplant 2009, 9:2552-2560. 10.1111/j.1600-6143.2009.02803.x, 19843033.
17. Shihab FS, Bennett WM, Yi H, Choi SO, Andoh TF. Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity. Kidney Int 2004, 65:1262-1271. 10.1111/j.1523-1755.2004.00498.x, 15086465.
18. Ninova D, Covarrubias M, Rea DJ, Park WD, Grande JP, Stegall MD. Acute nephrotoxicity of tacrolimus and sirolimus in renal isografts: differential intragraft expression of transforming growth factor-b1 and a-smooth muscle actin. Transplantation 2004, 78:338-344.
19. Sis B, Jhangri GS, Riopel J, Chang J, de Freitas DG, Hidalgo L, Mengel M, Matas A, Halloran PF. A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. Am J Transplant 2012, 12(5):1168-1179. 10.1111/j.1600-6143.2011.03931.x, 22300601.
20. Papadimitriou JC, Drachenberg CB, Ramos E, Kukuruga D, Klassen DK, Ugarte R, Nogueira J, Cangro C, Weir MR, Haririan A. Antibody-mediated allograft rejection: morphologic spectrum and serologic correlations in surveillance and for cause biopsies. Transplantation 2013, 95:128-136. 10.1097/TP.0b013e3182777f28, 23222897.
21. de Kort H, Willicombe M, Brookes P, Dominy KM, Santos-Nunez E, Galliford JW, Chan K, Taube D, McLean AG, Cook HT, Roufosse C. Microcirculation inflammation associates with outcome in renal transplant patients with de novo donor-specific antibodies. Am J Transplant 2013, 13:485-492. 10.1111/j.1600-6143.2012.04325.x, 23167441.
22. Kaneku H. Annual literature review of donor-specific HLA antibodies after organ transplantation. Clin Transpl 2011, 311-318.
23. Jackson AM, Lucas DP, Melancon JK, Desai NM. Clinical relevance and IgG subclass determination of non-HLA antibodies identified using endothelial cell precursors isolated from donor blood. Transplantation 2011, 92:54-60. 10.1097/TP.0b013e31821b60e9, 21516064.
24. Qin Z, Lavingia B, Zou Y, Stastny P. Antibodies against nucleolin in recipients of organ transplants. Transplantation 2011, 92:829-835. 10.1097/TP.0b013e31822d0977, 21869741.
25. Sigdel TK, Li L, Tran TQ, Khatri P, Naesens M, Sansanwal P, Dai H, Hsieh SC, Sarwal MM. Non-HLA antibodies to immunogenic epitopes predict the evolution of chronic renal allograft injury. J Am Soc Nephrol 2012, 23:750-763. 10.1681/ASN.2011060596, 22302197.
26. AlMahri A, Holgersson J, Alheim M. Detection of complement-fixing and nonfixing antibodies specific for endothelial precursor cells and lymphocytes using flow cytometry. Tissue Antigens 2012, 80:404-415. 10.1111/j.1399-0039.2012.01954.x, 22931381.
27. Bartel G, Wahrmann M, Schwaiger E, Kikić T, Winzer C, Hörl WH, Mühlbacher F, Hoke M, Zlabinger GJ, Regele H, Böhmig GA. Solid phase detection of C4d-fixing HLA antibodies to predict rejection in high immunological risk kidney transplant recipients. Transpl Int 2013, 26:121-130. 10.1111/tri.12000, 23145861.
28. Chen G, Sequeira F, Tyan DB. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum Immunol 2011, 72:849-858. 10.1016/j.humimm.2011.07.001, 21791230.
29. Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM, Cecka MJ, Cosyns JP, Demetris AJ, Fishbein MC, Fogo A, Furness P, Gibson IW, Glotz D, Hayry P, Hunsickern L, Kashgarian M, Kerman R, Magil AJ, Montgomery R, Morozumi K, Nickeleit V, Randhawa P, Regele H, Seron D, Seshan S, Sund S, Trpkov K. Antibody-mediated rejection criteria-an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003, 3(6):708-714. 10.1034/j.1600-6143.2003.00072.x, 12780562.
30. Sis B, Mengel M, Haas M, Colvin RB, Halloran PF, Racusen LC, Solez K, Baldwin WM, Bracamonte ER, Broecker V, Cosio F, Demetris AJ, Drachenberg C, Einecke G, Gloor J, Glotz D, Kraus E, Legendre C, Liapis H, Mannon RB, Nankivell BJ, Nickeleit V, Papadimitriou JC, Randhawa P, Regele H, Renaudin K, Rodriguez ER, Seron D, Seshan S, Suthanthiran M, Wasowska BA, Zachary A, et al. Banff' 09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010, 10(3):464-471. 10.1111/j.1600-6143.2009.02987.x, 20121738.
31. Kikić Z, Regele H, Nordmeyer V, Wahrmann M, Kletzmayr J, Bartel G, Böhmig GA. Significance of peritubular capillary, glomerular, and arteriolar C4d staining pat-terns in paraffin sections of early kidney transplant biopsies. Transplantation 2011, 91(4):440-446.
32. Valente M, Furian L, Della Barbera M, Silvestre C, Marino S, Seveso M, Cozzi E, Rigotti P, Aiello FB. Glomerular C4d immunoreactivity in acute rejection biopsies of renal transplant patients. Transplant Proc 2012, 44:1897-1900. 10.1016/j.transproceed.2012.07.062, 22974865.
33. Devos JM, Gaber AO, Teeter LD, Graviss EA, Patel SJ, Land GA, Moore LW, Knight RJ. Intermediate-term graft loss after renal transplantation is associated with both donor-specific antibody and acute rejection. Transplantation 2014, 97(5):534-540. 10.1097/01.TP.0000438196.30790.66, 24595116.
34. Brokhof MM, Sollinger HW, Hager DR, Muth BL, Pirsch JD, Fernandez LA, Bellingham JM, Mezrich JD, Foley DP, D'Alessandro AM, Odorico JS, Mohamed MA, Vidyasagar V, Ellis TM, Kaufman DB, Djamali A. Antithymocyte globulin is associated with a lower incidence of De novo donor-specific antibodies in moderately sensitized renal transplant recipients. Transplantation 2014, 97(6):612-617. 10.1097/TP.0000000000000031, 4106033, 24531846.
35. Chadban SJ, Wu H, Hughes J. Macrophages and kidney transplantation. Semin Nephrol 2010, 30(3):278-289. 10.1016/j.semnephrol.2010.03.009, 20620672.
36. Anders HJ, Ryu M. Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis. Kidney Int 2011, 80(9):915-925. 10.1038/ki.2011.217, 21814171.
37. Qi F, Adair A, Ferenbach D, Vass DG, Mylonas KJ, Kipari T, Clay M, Kluth DC, Hughes J, Marson LP. Depletion of cells of monocyte lineage prevents loss of renal microvasculature in murine kidney transplantation. Transplantation 2008, 86(9):1267-1274. 10.1097/TP.0b013e318188d433, 19005409.
38. Liu YH. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol 2011, 7(12):684-696. 10.1038/nrneph.2011.149, 22009250.
39. Zeisberg M, Kalluri R. Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis. Am J Physiol Cell Physiol 2013, 304(3):C216-C225. 10.1152/ajpcell.00328.2012, 3566435, 23255577.
40. Guarino M, Tosoni A, Nebuloni M. Direct contribution of epithelium to organ fibrosis: epithelial-mesenchymal transition. Hum Pathol 2009, 40(10):1365-1376. 10.1016/j.humpath.2009.02.020, 19695676.
41. Jiang T, Huang B, Chen PS, Ouyang J. Epithelial-mesenchymal transition of renal tubules: divergent processes of repairing in acute or chronic injury?. Med Hypotheses 2013, 81(1):73-75. 10.1016/j.mehy.2013.03.020, 23601763.
42. de Matos AC, Câmara NO, Tonato EJ, Durão Júnior Mde S, Franco MF, Moura LA, Pacheco-Silva A. Vimentin expression and myofibroblast infiltration are early markers of renal dysfunction in kidney transplantation: an early stage of chronic allograft dysfunction?. Transplant Proc 2010, 42(9):3482-3488. 10.1016/j.transproceed.2010.06.014, 21094801.
43. Boor P, Ostendorf T, Floege J. Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol 2010, 6:643-656.
44. Ortiz A, Ucero AC, Egido J. Unravelling fibrosis: two newcomers and an old foe. Nephrol Dial Transplant 2010, 25:3492-3495. 10.1093/ndt/gfq518, 20833689.
45. Wang Q, Usinger W, Nichols B, Gray J, Xu L, Seeley TW, Brenner M, Guo G, Zhang W, Oliver N, Lin A, Yeowell D. Cooperative interaction of CTGF and TGF-beta in animal models of fibrotic disease. Fibrogenesis Tissue Repair 2011, 4(1):4. 10.1186/1755-1536-4-4, 3042008, 21284856.
46. Yeh YC, Wei WC, Wang YK, Lin SC, Sung JM, Tang MJ. Transforming growth factor-beta1 induces Smad3-dependent beta1 integrin gene expression in epithelial-to-mesenchymal transition during chronic tubulointerstitial fibrosis. Am J Pathol 2010, 177:1743-1754. 10.2353/ajpath.2010.091183, 2947271, 20709799.
47. Zeng R, Han M, Luo Y, Li C, Pei G, Liao W, Bai S, Ge S, Liu X, Xu G. Role of Sema4C in TGF-beta1-induced mitogenactivated protein kinase activation and epithelial-mesenchymal transition in renal tubular epithelial cells. Nephrol Dial Transplant 2011, 26:1149-1156. 10.1093/ndt/gfq619, 3070071, 20959347.
48. Zhu B, Wang YJ, Zhu CF, Lin Y, Zhu XL, Wei S, Lu Y, Cheng XX. Triptolide inhibits extracellular matrix protein synthesis by suppressing the Smad2 but not the MAPK pathway in TGFbeta1-stimulated NRK-49 F cells. Nephrol Dial Transplant 2010, 25:3180-3191. 10.1093/ndt/gfq239, 20466671.
49. Djamali A, Samaniego M. Fibrogenesis in kidney transplantation: potential targets for prevention and therapy. Transplantation 2009, 88(10):1149-1156. 10.1097/TP.0b013e3181bcccea, 2784657, 19935366.
50. Khanna AK, Cairns VR, Becker CG, Hosenpud JD. Transforming growth factor (TGF)-beta mimics and anti-TGF-beta antibody abrogates thein vivoeffects of cyclosporine: demonstration of a direct role of TGF-beta in immunosuppression and nephrotoxicity of cyclosporine. Transplantation 1999, 67(6):882-889. 10.1097/00007890-199903270-00016, 10199738.
51. Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, Kalluri R. BMP-7 counteracts TGF-1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 2003, 9:964-968. 10.1038/nm888, 12808448.
52. Jenkins RH, Fraser DJ. BMP-6 emerges as a potential major regulator of fibrosis in the kidney. Am J Pathol 2011, 178:964-965. 10.1016/j.ajpath.2010.12.010, 3069840, 21356347.
53. Yan JD, Yang S, Zhang J, Zhu TH. BMP6 reverses TGF- 1-induced changes in HK-2 cells. Implications for the treatment of renal fibrosis. Acta Pharmacol Sin 2009, 30:994-1000. 10.1038/aps.2009.56, 4006648, 19543302.
54. Boon MR, van der Horst G, van der Pluijm G, Tamsma JT, Smit JW, Rensen PC. Bone morphogenetic protein 7. A broadspectrum growth factor with multiple target therapeutic potency. Cytokine Growth Factor Rev 2011, 22:221-229. 10.1016/j.cytogfr.2011.08.001, 21924665.
55. Gould SE, Day M, Jones SS, Dorai H. BMP-7 regulates chemokine, cytokine, and hemodynamic gene expression in proximal tubule cells. Kidney Int 2002, 61:51-60. 10.1046/j.1523-1755.2002.00103.x, 11786084.
56. Wang X, Oka T, Chow FL, Cooper SB, Odenbach J, Lopaschuk GD, Kassiri Z, Fernandez-Patron C. Tumor necrosis factor-alpha-converting enzyme is a key regulator of agonist-induced cardiac hypertrophy and fibrosis. Hypertension 2009, 54:575-582. 10.1161/HYPERTENSIONAHA.108.127670, 19581512.
57. Mulder GM, Melenhorst WB, Celie JW, Kloosterhuis NJ, Hillebrands JL, Ploeg RJ, Seelen MA, Visser L, van Dijk MC, van Goor H. ADAM17 up-regulation in renal transplant dysfunction and non-transplant-related renal fibrosis. Nephrol Dial Transplant 2012, 27:2114-2122. 10.1093/ndt/gfr583, 22015440.
58. Park WD, Griffin MD, Cornell LD, Cosio FG, Stegall MD. Fibrosis with inflammation at one year predicts transplant functional decline. J Am Soc Nephrol 2010, 21:1987-1997. 10.1681/ASN.2010010049, 3014013, 20813870.
59. Sellarés J, de Freitas DG, Mengel M, Sis B, Hidalgo LG, Matas AJ, Kaplan B, Halloran PF. Inflammation lesions in kidney transplant biopsies: association with survival is due to the underlying diseases. Am J Transplant 2011, 11:489-499. 10.1111/j.1600-6143.2010.03415.x, 21342447.
60. De Serres SA, Vadivel N, Mfarrej BG, Grafals M, DeJoseph M, Dyer C, Magee CN, Chandraker A, Gallon LG, Najafian N. Monocyte-secreted inflammatory cytokines are associated with transplant glomerulopathy in renal allograft recipients. Transplantation 2011, 91:552-559. 10.1097/TP.0b013e318205b3c1, 21150704.
61. Grebe SO, Kuhlmann U, Fogl D, Luyckx VA, Mueller TF. Macrophage activation is associated with poorer long-term outcomes in renal transplant patients. Clin Transpl 2011, 25:744-754.
62. Yu TM, Wen MC, Li CY, Cheng CH, Wu MJ, Chen CH, Shu KH. Expression of hypoxia-inducible factor-1α (HIF-1α) in infiltrating inflammatory cells is associated with chronic allograft dysfunction and predicts long-term graft survival. Nephrol Dial Transplant 2013, 28:659-670. 10.1093/ndt/gfs377, 23028107.
63. Eltzschig HK. Targeting hypoxia-induced inflammation. Anesthesiology 2011, 114:239-242. 10.1097/ALN.0b013e3182070c66, 3074366, 21239967.
64. Luo L, Luo G, Fang Q, Sun Z. Stable expression of hypoxia-inducible factor-1α in human renal proximal tubular epithelial cells promotes epithelial to mesenchymal transition. Transplant Proc 2014, 46(1):130-134. 10.1016/j.transproceed.2013.06.024, 24507038.
65. Sakai N, Wada T, Yokoyama H, Lipp M, Ueha S, Matsushima K, Kaneko S. Secondary lymphoid tissue chemokine (SLC/CCL21)/CCR7 signaling regulates fibro-cytes in renal fibrosis. Proc Natl Acad Sci U S A 2006, 103(38):14098-14103. 10.1073/pnas.0511200103, 1599918, 16966615.
66. Strutz F, Zeisberg M. Renal fibroblasts and myofibroblasts in chronic kidney disease. J Am Soc Nephrol 2006, 17(11):2992-2998. 10.1681/ASN.2006050420, 17035610.
67. Zhou HL, Wang YT, Gao T, Wang WG, Wang YS. Distribution and expression of fibroblast-specific protein chemokine CCL21 and chemokine receptor CCR7 in renal allografts. Transplant Proc 2013, 45:38-45. 10.1016/j.transproceed.2012.10.026, 23375273.
68. Vostálová J, Galandáková A, Strebl P. Zadražil: oxidative stress in patients after kidney transplantation. Vnitr Lek 2013, 59(4):296-300.
69. Fonseca I, Reguengo H, Almeida M, Dias L, Martins LS, Pedroso S, Santos J, Lobato L, Henriques AC, Mendonça D. Oxidative stress in kidney transplantation: malondialdehyde is an early predictive marker of graft dysfunction. Transplantation 2014, 97(10):1058-1065. 10.1097/01.TP.0000438626.91095.50, 24406454.
70. Meng XM, Nikolic-Paterson DJ, Lan HY. Inflammatory processes in renal fibrosis. Nat Rev Nephrol 2014, 10(9):493-503. 10.1038/nrneph.2014.114, 24981817.
71. Hueso M, Navarro E, Moreso F, O'Valle F, Pérez-Riba M, Del Moral RG, Grinyó JM, Serón D. Intragraft expression of the IL-10 gene is up-regulated in renal protocol biopsies with early interstitial fibrosis, tubular atrophy, and subclinical rejection. Am J Pathol 2010, 176:1696-1704. 10.2353/ajpath.2010.090411, 2843461, 20150436.
72. Lange-Sperandio B, Trautmann A, Eickelberg O, Jayachandran A, Oberle S, Schmidutz F, Rodenbeck B, Hömme M, Horuk R, Schaefer F. Leukocytes induce epithelial to mesenchymal transition after unilateral ureteral obstruction in neonatal mice. Am J Pathol 2007, 171:861-871. 10.2353/ajpath.2007.061199, 1959504, 17675578.
73. Guillén-Gómez E, Guirado L, Belmonte X, Maderuelo A, Santín S, Juarez C, Ars E, Facundo C, Ballarín JA, Vidal S, Díaz-Encarnación MM. Monocyte implication in renal allograft dysfunction. Clin Exp Immunol 2013, 175:323-331.
74. Tan RJ, Liu Y. Matrix metalloproteinases in kidney homeostasis and diseases. Am J Physiol Renal Physiol 2012, 302:F1351-F1361. 10.1152/ajprenal.00037.2012, 3774496, 22492945.
75. Rodder S, Scherer A, Korner M, Marti HP. A subset of metzincins and related genes constitutes a marker of human solid organ fibrosis. Virchows Arch 2011, 458:487-496. 10.1007/s00428-011-1052-7, 21337037.
76. Wong W, DeVito J, Nguyen H, Sarracino D, Porcheray F, Dargon I, Pelle PD, Collins AB, Tolkoff-Rubin N, Smith RN, Colvin R, Zorn E. Chronic humoral rejection of human kidney allografts is associated with MMP-2 accumulation in podocytes and its release in the urine. Am J Transplant 2010, 10:2463-2471. 10.1111/j.1600-6143.2010.03290.x, 3805271, 20977637.
77. Mazanowska O, Kamińska D, Krajewska M, Banasik M, Zabińska M, Kościelska-Kasprzak K, Biecek P, Chudoba P, Patrzałek D. Increased plasma tissue inhibitors of metalloproteinase concentrations as negative predictors associated with deterioration of kidney allograft function upon long-term observation. Transplant Proc 2013, 45:1458-1461. 10.1016/j.transproceed.2013.02.109, 23726596.
78. Rödder S, Scherer A, Raulf F, Berthier CC, Hertig A, Couzi L, Durrbach A, Rondeau E, Marti HP. Renal allografts with IF/TA display distinct expression profiles of metzincins and related genes. Am J Transplant 2009, 9:517-526. 10.1111/j.1600-6143.2008.02512.x, 19191772.
79. Yan Q, Sui W, Wang B, Zou H, Zou G, Luo H. Expression of MMP-2 and TIMP-1 in renal tissue of patients with chronic active antibody-mediated renal graft rejection. Diagn Pathol 2012, 7:141. 10.1186/1746-1596-7-141, 3539883, 23057632.
80. Starzl TE, Demetris AJ, Murase N, Ildstad S, Ricordi C, Trucco M. Cell migration, chimerism, and graft acceptance. Lancet 1992, 339:1579-1582. 10.1016/0140-6736(92)91840-5, 2950640, 1351558.
81. Starzl TE, Demetris AJ, Trucco M, Zeevi A, Ramos H, Terasaki P, Rudert WA, Kocova M, Ricordi C, Ildstad S. Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation 1993, 55:1272-1277. 10.1097/00007890-199306000-00012, 2953386, 8516813.
82. Tajik N, Singal D, Pourmand G, Ebrahimi-Rad M, Radjabzadeh M, Tavasoli P, Khosravi F, Nikbin B. Prospective study of microchimerism in renal allograft recipients: association between HLA-DR matching, microchimerism and acute rejection. Clin Transplant 2001, 15:192-198. 10.1034/j.1399-0012.2001.150308.x, 11389710.
83. Pujal JM, Grinyó JM, Manito N, Gil-Vernet S, Hueso M, Caldés A, Costa S, Benéitez D, Grañena A, Gallardo D. Influence of hematopoietic microchimerism in organ tolerance after kidney or heart transplantation. Transplant Proc 2003, 35:1775-1777. 10.1016/S0041-1345(03)00703-6, 12962791.
84. Yao-Wen F, Wei-Gang W, Hong-Lan Z, Lu C. Presence of donor-and-recipient-derived DNA microchimerism in the cell-free blood samples of renal transplantation recipients associates with the acceptance of transplanted kidneys. Asian J Androl 2006, 8(4):477-482. 10.1111/j.1745-7262.2006.00147.x, 16763725.
85. Cosimi AB, Sachs DH. Mixed chimerism and transplantation tolerance. Transplantation 2004, 77:943-946. 10.1097/01.TP.0000117779.23431.3F, 15077044.
86. Claas F. Chimerism as a tool to induce clinical transplantation tolerance. Curr Opin Immunol 2004, 16:578-583. 10.1016/j.coi.2004.07.006, 15342002.
87. Starzl TE. Chimerism and tolerance in transplantation. Proc Natl Acad Sci U S A 2004, 101(Suppl 2):14607-14614. 521985, 15319473.
88. Ju W, Smith S, Kretzler M. Genomic biomarkers for chronic kidney disease. Transl Res 2012, 159:290-302. 10.1016/j.trsl.2012.01.020, 3329158, 22424432.
89. Perkins D, Verma M, Park KJ. Advances of genomic science and systems biology in renal transplantation: a review. Semin Immunopathol 2011, 33:211-218. 10.1007/s00281-011-0243-2, 3082700, 21318414.
90. Beltrami C, Clayton A, Phillips AO, Fraser DJ, Bowen T. Analysis of urinary microRNAs in chronic kidney disease. Biochem Soc Trans 2012, 40:875-879. 10.1042/BST20120090, 22817751.
91. Afaneh C, Muthukumar T, Lubetzky M, Ding R, Snopkowski C, Sharma VK, Seshan S, Dadhania D, Schwartz JE, Suthanthiran M. Urinary cell levels of mRNA for OX40, OX40L, PD-1, PD-L1, or PD-L2 and acute rejection of human renal allografts. Transplantation 2010, 90:1381-1387. 10.1097/TP.0b013e3181ffbadd, 3033230, 21079547.
92. He W, Tan RJ, Li Y, Wang D, Nie J, Hou FF, Liu Y. Matrix metalloproteinase-7 as a surrogate marker predicts renal Wnt/b -catenin activity in CKD. J Am Soc Nephrol 2012, 23:294-304. 10.1681/ASN.2011050490, 3269179, 22095947.
93. Bonventre JV. Kidney injury molecule-1 (KIM-1): a urinary biomarker and much more. Nephrol Dial Transplant 2009, 24:3265. 10.1093/ndt/gfp010, 19318357.
94. Nogare AL, Dalpiaz T, Veronese FJ, Gonçalves LF, Manfro RC. Noninvasive analyses of kidney injury molecule-1 messenger RNA in kidney transplant recipients with graft dysfunction. Transplant Proc 2012, 44:2297-2299. 10.1016/j.transproceed.2012.07.047, 23026578.
95. Lorenzen JM, Volkmann I, Fiedler J, Schmidt M, Scheffner I, Haller H, Gwinner W, Thum T. Urinary miR-210 as a mediator of acute T-cell mediated rejection in renal allograft recipients. Am J Transplant 2011, 11:2221-2227. 10.1111/j.1600-6143.2011.03679.x, 21812927.
96. Scian MJ, Maluf DG, David KG, Archer KJ, Suh JL, Wolen AR, Mba MU, Massey HD, King AL, Gehr T, Cotterell A, Posner M, Mas V. MicroRNA profiles in allograft tissues and paired urines associate with chronic allograft dysfunction with IF/TA. Am J Transplant 2011, 11:2110-2122. 10.1111/j.1600-6143.2011.03666.x, 3184368, 21794090.
97. Maluf DG, Dumur CI, Suh JL, Scian MJ, King AL, Cathro H, Lee JK, Gehrau RC, Brayman KL, Gallon L, Mas VR. The urine microRNA profile may help monitor post-transplant renal graft function. Kidney Int 2014, 85(2):439-449. 10.1038/ki.2013.338, 3946645, 24025639.
98. Carr MW, Roth SJ, Luther E, Rose SS, Springer TA. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci U S A 1994, 91(9):3652-3656. 10.1073/pnas.91.9.3652, 43639, 8170963.
99. Allavena P, Bianchi G, Zhou D, van Damme J, Jílek P, Sozzani S, Mantovani A. Induction of natural killer cell migration by monocyte chemotactic protein-1, -2, and -3. Eur J Immunol 1994, 24(12):3233-3236. 10.1002/eji.1830241249, 7805752.
100. Ho J, Rush DN, Gibson IW, Karpinski M, Storsley L, Bestland J, Stefura W, HayGlass KT, Nickerson PW. Early urinary CCL2 is associated with the later development of interstitial fibrosis and tubular atrophy in renal allografts. Transplantation 2010, 90(4):394-400. 10.1097/TP.0b013e3181e6424d, 20625355.
101. Shi Y, Tu Z, Bao J, Sun H, Wang W, Luo G, Li S, Li Y, Bu H. Urinary connective tissue growth factor increases far earlier than histopathological damage and functional deterioration in early chronic renal allograft injury. Scand J Urol Nephrol 2009, 43(5):390-399. 10.3109/00365520903142244, 19921985.
102. Mirković K, Doorenbos CR, Dam WA, Lambers Heerspink HJ, Slagman MC, Nauta FL, Kramer AB, Gansevoort RT, van den Born J, Navis G, de Borst MH. Urinary vitamin D binding protein: a potential novel marker of renal interstitial inflammation and fibrosis. PLoS One 2013, 8(2):e55887. 10.1371/journal.pone.0055887, 3569442, 23409077.
103. Amer H, Lieske JC, Rule AD, Kremers WK, Larson TS, Franco Palacios CR, Stegall MD, Cosio FG. Urine high and Low molecular weight proteins One-year post-kidney transplant: relationship to histology and graft survival. Am J Transplant 2013, 13:676-684. 10.1111/ajt.12044, 3582782, 23414180.
104. Li Y, Ge Y, Liu FY, Peng YM, Sun L, Li J, Chen Q, Sun Y, Ye K. Norcantharidin, a protective therapeutic agent in renal tubulointerstitial fibrosis. Mol Cell Biochem 2012, 361(1-2):79-83.
105. Li Y, Sun Y, Liu F, Sun L, Li J, Duan S, Liu H, Peng Y, Xiao L, Liu Y, Xi Y, You Y, Li H, Wang M, Wang S, Hou T. Norcantharidin inhibits renal interstitial fibrosis by blocking the tubular epithelial-mesenchymal transition. PLoS One 2013, 8(6):e66356. 10.1371/journal.pone.0066356, 3692527, 23825538.
106. Lee SH, Li C, Lim SW, Ahn KO, Choi BS, Kim YS, Moon IS, Kim J, Bang BK, Yang CW. Attenuation of interstitial inflammation and fibrosis by recombinant human erythropoietin in chronic cyclosporine nephropathy. Am J Nephrol 2005, 25(1):64-76. 10.1159/000084275, 15746540.
107. Park SH, Choi MJ, Song IK, Choi SY, Nam JO, Kim CD, Lee BH, Park RW, Park KM, Kim YJ, Kim IS, Kwon TH, Kim YL. Erythropoietin decreases renal fibrosis in mice with ureteral obstruction: role of inhibiting TGF-beta-induced epithelial-to-mesenchymal transition. J Am Soc Nephrol 2007, 18(5):1497-1507. 10.1681/ASN.2005080866, 17389738.
108. Bienaimé F, Girard D, Anglicheau D, Canaud G, Souberbielle JC, Kreis H, Noël LH, Friedlander G, Elie C, Legendre C, Prié D. Vitamin D status and outcomes after renal transplantation. J Am Soc Nephrol 2013, 24(5):831-841. 10.1681/ASN.2012060614, 3636791, 23539758.
109. Ito I, Waku T, Aoki M, Abe R, Nagai Y, Watanabe T, Nakajima Y, Ohkido I, Yokoyama K, Miyachi H, Shimizu T, Murayama A, Kishimoto H, Nagasawa K, Yanagisawa J. A nonclassical vitamin D receptor pathway suppresses renal fibrosis. J Clin Invest 2013, 123(11):4579-4594. 10.1172/JCI67804, 3809783, 24135137.
110. Bonventre JV. Antifibrotic vitamin D analogs. J Clin Invest 2013, 123(11):4570-4573. 10.1172/JCI72748, 3809811, 24162671.
111. Wu MJ, Wen MC, Chiu YT, Chiou YY, Shu KH, Tang MJ. Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. Kidney Int 2006, 69(11):2029-2036. 10.1038/sj.ki.5000161, 16732193.
112. Yin JL, Wyburn K, Wu H, Eris JM, Hambly BD, Chadban SJ. Sirolimus reduces vasculopathy but exacerbates proteinuria in association with inhibition of VEGF and VEGFR in a rat kidney model of chronic allograft dysfunction. Nephrol Dial Transplant 2013, 28(2):327-336. 10.1093/ndt/gfs453, 23229928.
113. Özdemir BH, Özdemir AA, Erdal R, Özdemir FN, Haberal M. Rapamycin prevents interstitial fibrosis in renal allografts through decreasing angiogenesis and inflammation. Transplant Proc 2011, 43(2):524-526. 10.1016/j.transproceed.2011.01.080, 21440750.
114. Campistol JM, Inigo P, Larios S, Bescos M, Oppenheimer F. Role of transforming growth factor-beta1 in the progression of chronic allograft nephropathy. Nephrol Dial Transplant 2001, 16:114-116.
115. Robertson H, Ali S, McDonnell BJ, Burt AD, Kirby JA. Chronic renal allograft dysfunction: the role of T cell-mediated tubular epithelial to mesenchymal cell transition. J Am Soc Nephrol 2004, 15:390-397. 10.1097/01.ASN.0000108521.39082.E1, 14747385.
116. Schnaper HW, Hayashida T, Hubchak SC, Poncelet AC. TGF-β signal transduction and mesangial cell fibrogenesis. Am J Physiol Renal Physiol 2003, 284:F243-F252. 10.1152/ajpcell.00305.2002, 12529270.
117. Strutz F, Zeisberg M, Ziyadeh FN, Yang CQ, Kalluri R, Muller GA, Neilson EG. Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int 2002, 61:1714-1728. 10.1046/j.1523-1755.2002.00333.x, 11967021.
118. Zeisberg M, Bonner G, Maeshima Y, Colorado P, Muller GA, Strutz F, Kalluri R. Renal fibrosis: collagen composition and assembly regulates epithelial-mesenchymal transdifferentiation. Am J Pathol 2001, 159:1313-1321. 10.1016/S0002-9440(10)62518-7, 1850511, 11583959.
119. Mannon RB. Therapeutic targets in the treatment of allograft fibrosis. Am J Transplant 2006, 6:867-875. 10.1111/j.1600-6143.2006.01261.x, 16611322.
120. Dasch JR, Pace DR, Waegell W, Inenaga D, Ellingsworth L. Monoclonal antibodies recognizing transforming growth factor-beta. Bioactivity neutralization and transforming growth factor beta 2 affinity purification. J Immunol 1989, 142:1536-1541.
121. Guan Q, Li S, Gao S, Chen H, Nguan CY, Du C. Reduction of chronic rejection of renal allografts by anti-transforming growth factor-β antibody therapy in a rat model. Am J Physiol Renal Physiol 2013, 305(2):F199-F207. 10.1152/ajprenal.00665.2012, 23552866.
122. Luo DD, Phillips A, Fraser D. Bone morphogenetic protein-7 inhibits proximal tubular epithelial cell Smad3 signaling via increased SnoN expression. Am J Pathol 2010, 176:1139-1147. 10.2353/ajpath.2010.090459, 2832137, 20093492.
123. Zeisberg M. Bone morphogenic protein-7 and the kidney: current concepts and open questions. Nephrol Dial Transplant 2006, 21:568-573. 10.1093/ndt/gfk010, 16373388.
124. Maciel TT, Kempf H, Campos AH. Targeting bone morphogenetic protein signaling on renal and vascular diseases. Curr Opin Nephrol Hypertens 2010, 19:26-31. 10.1097/MNH.0b013e328332fc13, 19823085.
125. Bhatti F, Mankhey RW, Asico L, Quinn MT, Welch WJ, Maric C. Mechanisms of antioxidant and pro-oxidant effects of alpha-lipoic acid in the diabetic and nondiabetic kidney. Kidney Int 2005, 67(4):1371-1380. 10.1111/j.1523-1755.2005.00214.x, 15780089.
126. Wongmekiat O, Leelarungrayub D, Thamprasert K. Alpha-lipoic acid attenuates renal injury in rats with obstructive nephropathy. Biomed Res Int 2013, 2013:138719. 3830861, 24288661.
127. Sehirli O, Sener E, Cetinel S, Yüksel M, Gedik N, Sener G. Alpha-lipoic acid protects against renal ischaemia-reperfusion injury in rats. Clin Exp Pharmacol Physiol 2008, 35(3):249-255. 10.1111/j.1440-1681.2007.04810.x, 17941895.
128. Bunnag S, Einecke G, Reeve J, Jhangri GS, Mueller TF, Sis B, Hidalgo LG, Mengel M, Kayser D, Kaplan B, Halloran PF. Molecular correlates of renal function in kidney transplant biopsies. J Am Soc Nephrol 2009, 20:1149-1160. 10.1681/ASN.2008080863, 2678047, 19389845.
129. Celie JW, Katta KK, Adepu S, Melenhorst WB, Reijmers RM, Slot EM, Beelen RH, Spaargaren M, Ploeg RJ, Navis G, van der Heide JJ, van Dijk MC, van Goor H, van den Born J. Tubular epithelial syndecan-1 maintains renal function in murine ischemia/reperfusion and human transplantation. Kidney Int 2012, 81:651-661. 10.1038/ki.2011.425, 22237752.
130. Lorber MI, Mulgaonkar S, Butt KM, Elkhammas E, Mendez R, Rajagopalan PR, Kahan B, Sollinger H, Li Y, Cretin N, Tedesco H, B251 Study Group Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 2005, 80:244-252. 10.1097/01.TP.0000164352.65613.24, 16041270, B251 Study Group.
131. Nashan B, Curtis J, Ponticelli C, Mourad G, Jaffe J, Haas T, 156 Study Group Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. Transplantation 2004, 78:1332-1340. 10.1097/01.TP.0000140486.97461.49, 15548972, 156 Study Group.
132. Tedesco-Silva H, Vitko S, Pascual J, Eris J, Magee JC, Whelchel J, Civati G, Campbell S, Alves-Filho G, Bourbigot B, Garcia VD, Leone J, Esmeraldo R, Rigotti P, Cambi V, Haas T, 2306 and 2307 study groups 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transpl Int 2007, 20:27-36. 10.1111/j.1432-2277.2006.00414.x, 17181650, 2306 and 2307 study groups.
133. Tedesco Silva H, Cibrik D, Johnston T, Lackova E, Mange K, Panis C, Walker R, Wang Z, Zibari G, Kim YS. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 2010, 10:1401-1413. 10.1111/j.1600-6143.2010.03129.x, 20455882.
134. Chan L, Hartmann E, Cibrik D, Cooper M, Shaw LM. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. Transplantation 2010, 90:31-37.
135. Holdaas H, Bentdal O, Pfeffer P, Mjørnstedt L, Solbu D, Midtvedt K. Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study. Clin Transplant 2008, 22:366-371. 10.1111/j.1399-0012.2008.00795.x, 18279419.
136. Zhou HP, Yi DH, Yu SQ, Sun GC, Cui Q, Zhu HL, Liu JC, Zhang JZ, Wu TJ. Administration of donor-derived mesenchymal stem cells can prolong the survival of rat cardiac allograft. Transplant Proc 2006, 38:3046-3051. 10.1016/j.transproceed.2006.10.002, 17112896.
137. Ge W, Jiang J, Baroja ML, Arp J, Zassoko R, Liu W, Bartholomew A, Garcia B, Wang H. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transplant 2009, 9:1760-1772. 10.1111/j.1600-6143.2009.02721.x, 19563344.
138. Franquesa M, Herrero E, Torras J, Ripoll E, Flaquer M, Gomà M, Lloberas N, Anegon I, Cruzado JM, Grinyó JM, Herrero-Fresneda I. Mesenchymal stem cell therapy prevents interstitial fibrosis and tubular atrophy in a rat kidney allograft model. Stem Cells Dev 2012, 21(17):3125-3135. 10.1089/scd.2012.0096, 3495114, 22494435.
139. Cavaglieri RC, Martini D, Sogayar MC, Noronha IL. Mesenchymal stem cells delivered at the subcapsule of the kidney ameliorate renal disease in the rat remnant kidney model. Transplant Proc 2009, 41:947-951. 10.1016/j.transproceed.2009.01.072, 19376395.
140. Choi S, Park M, Kim J, Hwang S, Park S, Lee Y. The role of mesenchymal stem cells in the functional improvement of chronic renal failure. Stem Cells Dev 2009, 18:521-529. 10.1089/scd.2008.0097, 18647091.
141. Ninichuk V, Gross O, Segerer S, Hoffmann R, Radomska E, Buchstaller A, Huss R, Akis N, Schlondorff D, Anders HJ. Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice. Kidney Int 2006, 70:121-129. 10.1038/sj.ki.5001521, 16723981.
142. Perico N, Casiraghi F, Introna M, Gotti E, Todeschini M, Cavinato RA, Capelli C, Rambaldi A, Cassis P, Rizzo P, Cortinovis M, Marasà M, Golay J, Noris M, Remuzzi G. Autologous mesenchymal stromal cells and kidney trans-plantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol 2011, 6:412-422. 10.2215/CJN.04950610, 3052234, 20930086.